Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Recruiting now · Phase 2

Conditions studied: Esophageal Squamous Cell Carcinoma (ESCC)

In brief

This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.

Key facts

Study ID

NCT07595770

Run by

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

People needed

37

Starts

2026-05-22

Expected to finish

2029-10-01

Last updated by the study team

2026-05-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• - 1. Provided informed consent and sign the informed consent form;
• 2. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
• 3. Pathological confirmed ESCC;
• 4. Patients assessed by thoracic oncologists as resectable without distant metastasis
• 5. Patients evaluate with clinical staging of T1-4aN1-3M0 or T3-4aN0M0(AJCC 9.0) based on imaging and pathological examination results;
• 6. Have at least one assessable lesion according to the RECIST V1.1
• 7. ECOG-PS score: 0-1;
• 8. Patients with normal function of organs such as heart, brain, lungs, and kidneys who can tolerate surgery;
• 9. With a life expectancy of ≥ 6 weeks;
• 10. Adequate major organ function without severe hematologic, cardiac, pulmonary, hepatic, renal, or bone marrow dysfunction, and no immunodeficiency disease;

You may not qualify if…

• 1. Patients who have received or are currently receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy
• 2. Patients with distant metastasis or inability to undergo resection after evaluation by thoracic surgeons
• 3. Simultaneously developing tumors in other parts of the body
• 4. Severe impairment of heart, liver, and kidney function (heart function grade 3-4, ALT and/or AST exceeding the upper limit of normal by more than 1.5 times, Cr (serum creatinine) exceeding the upper limit of normal by more than 1.5 times)
• 5. Patients with a history of autoimmune diseases who were receiving immunosuppressive therapy prior to enrollment, with immunosuppressive doses>10 mg/day or oral prednisone for more than 2 weeks
• 6. Severe allergy to immune preparations
• 7. Abnormal coagulation function: (PT>16s, APTT>53s, TT>21s, Fib<1.5 g/L), bleeding tendency or during thrombolytic or anticoagulant therapy
• 8. Pregnancy or lactation period
• 9. Other situations as judged by investigators not suitable for inclusion.;

Where it is running

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.